Argenx announces uk mhra approval of vyvgart for the treatment of generalized myasthenia gravis

Vyvgart is the first neonatal fc receptor (fcrn) blocker approved in the uk for the treatment of adults living with generalized myasthenia gravis ( gmg) who are anti-acetylcholine receptor (achr) antibody positive

ARGX Ratings Summary

ARGX Quant Ranking